相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The importance of influenza vaccination during the COVID-19 pandemic
John McCauley et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)
The disease burden of influenza beyond respiratory illness
Alejandro E. Macias et al.
VACCINE (2021)
Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis
Jason K. H. Lee et al.
VACCINE (2021)
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Rajeka Lazarus et al.
LANCET (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
Lindsey R. Baden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Adam Booth et al.
PLOS ONE (2021)
Introductory paper: High-dose influenza vaccine Preface
Mia Diaco et al.
VACCINE (2021)
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu et al.
VACCINE (2021)
Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic
Julian W. Tang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas et al.
LANCET (2021)
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 dose-ranging study ,
Paul A. Goepfert et al.
LANCET INFECTIOUS DISEASES (2021)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Amy Flaxman et al.
LANCET (2021)
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
Angela Choi et al.
NATURE MEDICINE (2021)
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Yinon M. Bar-On et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
Mark W. Tenforde et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
Eli S. Rosenberg et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
Wesley H. Self et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial
Lee-Jah Chang et al.
VACCINE (2019)
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
A. Danielle Iuliano et al.
LANCET (2018)
Vaccination in the elderly: The challenge of immune changes with aging
Annalisa Ciabattini et al.
SEMINARS IN IMMUNOLOGY (2018)
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Carlos A. DiazGranados et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults
David P. Greenberg et al.
VACCINE (2013)
Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2009)